Patents Assigned to Serenex, Inc.
-
Patent number: 8309548Abstract: Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein R1, R2, R3, R4, R5, R6, R7, n, Q1, Q2, Q3, Y, and X1-X4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.Type: GrantFiled: April 7, 2011Date of Patent: November 13, 2012Assignee: Serenex, Inc.Inventors: Kenneth He Huang, Jeron Eaves, Gunnar Hanson, James Veal, Thomas Barta, Lifeng Geng, Lindsay Hinkley
-
Publication number: 20110183977Abstract: Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein R1, R2, R3, R4, R5, R6, R7, n, Q1, Q2, Q3, Y, and X1-X4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.Type: ApplicationFiled: April 7, 2011Publication date: July 28, 2011Applicant: Serenex, Inc.Inventors: Kenneth He Huang, Jeron Eaves, Gunnar J. Hanson, James Veal, Thomas Barta, Lifeng Geng, Lindsay Hinkley
-
Patent number: 7928135Abstract: Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein R1, R2, R3, R4, R5, R6, R7, n, Q1, Q2, Q3, Y, and X1-X4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.Type: GrantFiled: October 19, 2010Date of Patent: April 19, 2011Assignee: Serenex, Inc.Inventors: Kenneth He Huang, Jeron Eaves, Gunnar Hanson, James Veal, Thomas Barta, Lifeng Geng, Lindsay Hinkley
-
Patent number: 7906529Abstract: Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein R1, R2, R3, R4, R5, R6, R7, n, Q1, Q2, Q3, Y, and X1-X4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.Type: GrantFiled: December 19, 2007Date of Patent: March 15, 2011Assignee: Serenex, Inc.Inventors: Kenneth He Huang, Jeron Eaves, Gunnar Hanson, James Veal, Thomas Barta, Lifeng Geng, Lindsay Hinkley
-
Publication number: 20110034529Abstract: Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein R1, R2, R3, R4, R5, R6, R7, n, Q1, Q2, Q3, Y, and X1-X4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.Type: ApplicationFiled: October 19, 2010Publication date: February 10, 2011Applicant: Serenex, Inc.Inventors: Kenneth He Huang, Jeron Eaves, Gunnar J. Hanson, James Veal, Thomas Barta, Lifeng Geng, Lindsay Hinkley
-
Patent number: 7678803Abstract: The current invention is directed toward compounds and pharmaceutically acceptable salts of Formula I wherein Q1 is CR1, Q2 is N, Q4 and Q5 are each CR1, Q3 is CR2, X1 is N or CRc, Y is CRc, X2 and X3 are each C(R5)(R6), R7 is O. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer The current invention is also directed toward pharmaceutical compositions comprising compounds of the invention.Type: GrantFiled: August 24, 2007Date of Patent: March 16, 2010Assignee: Serenex, Inc.Inventors: Kenneth He Huang, James Veal, Thomas Barta, Emilie D. Smith, Wei Ma, Andy Ommen
-
Patent number: 7371852Abstract: Alkyl-linked nucleotide non-homogeneous solid supports and nucleotide affinity media comprising an alkyl-linked nucleotide are provided. The linker is generally a hydrophobic linker that can be a 3, 4, 5, 6, 7, 8, 9, 10, or a longer carbon chain. Also included in the invention are methods for synthesis of an alkyl-linked nucleotide, nucleotide affinity media and methods of use thereof for affinity chromatography and screening methods.Type: GrantFiled: January 21, 2004Date of Patent: May 13, 2008Assignee: Serenex, Inc.Inventors: Klass P. Hardeman, Steven E. Hall, Roy W. Ware, Lindsay A. Hinkley, Matthew G. Jenks
-
Patent number: 7358370Abstract: Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein R1, R2, R3, R4, R5, R6, R7, n, Q1, Q2, Q3, Y, and X1-X4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.Type: GrantFiled: February 27, 2006Date of Patent: April 15, 2008Assignee: Serenex, Inc.Inventors: Kenneth He Huang, Jeron Eaves, Gunnar J. Hanson, James Veal, Thomas Barta, Lifeng Geng, Lindsay Hinkley
-
Patent number: 7282506Abstract: Disclosed are compounds of formula A: and pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, R3, R21, A1, A2, X, and Z are as defined herein. Compounds of formula A are useful in the treatment of diseases and/or conditions related to cell differentiation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.Type: GrantFiled: August 3, 2005Date of Patent: October 16, 2007Assignee: Serenex, Inc.Inventors: Gunnar J. Hanson, Roy W. Ware, Jr., Thomas E. Barta, He Huang
-
Publication number: 20070212690Abstract: The present invention provides methods for identifying improved folate antagonists. The improved folate antagonists identified by the methods of the invention have increased selectivity. The increased selectivity of the folate antagonists results in a reduced risk of adverse effects following treatment with the improved folate antagonists. The improved folate antagonists are identified based on their reduced binding affinity for at least one enzyme selected from glutathione synthase, pyruvate carboxylase, propionyl-CoA carboxylase, biotin carboxylase, acetyl-CoA carboxylase, and methylcrotonyl-CoA carboxylase. According to the invention, folate antagonists having reduced affinity for at least one enzyme selected from this group of enzymes are selected for the treatment of neoplastic, hyperproliferative, and immune disorders.Type: ApplicationFiled: October 28, 2004Publication date: September 13, 2007Applicant: Serenex, Inc.Inventor: Jeffrey Partridge
-
Publication number: 20060074105Abstract: The present invention provides composition and methods of inhibiting quinone reductase 2 (QR2). The methods are useful in the treatment of malaria and autoimmune diseases. The compositions of the invention comprise quinoline and quinazoline derivatives. The invention also provides methods for inhibiting the activity of QR2 by contacting the enzyme with one or more compositions of the invention.Type: ApplicationFiled: September 16, 2005Publication date: April 6, 2006Applicant: Serenex, Inc.Inventors: Roy Ware, Lindsay Hinkley, Klaas Hardeman, Matthew Jenks
-
Publication number: 20060035901Abstract: The present invention provides novel derivatives of MTX. The novel derivatives have increased selectivity, inhibit the activity of Her2, EGFR, or B-Raf to a greater degree than MTX, and display greater antiproliferative activity than MTX. Also provided are pharmaceutical compositions containing the novel derivatives, to methods of preparation of such derivatives, to methods of inhibiting the biological activity of polypeptides, methods of inhibiting cell proliferation, and the use of the novel compounds in therapy, particularly for the treatment of neoplastic, hyperproliferative, and immune disorders, including cancer, arthritis, and psoriasis.Type: ApplicationFiled: July 21, 2005Publication date: February 16, 2006Applicant: Serenex, Inc.Inventors: Gunnar Hanson, Thomas Barta, James Veal, Roy Ware
-
Publication number: 20040215009Abstract: Alkyl-linked nucleotide compositions and nucleotide affinity media comprising an alkyl-linked nucleotide are provided. The linker is generally a hydrophobic linker that can be a 3, 4, 5, 6, 7, 8, 9, 10, or a longer carbon chain. Also included in the invention are methods for synthesis of an alkyl-linked nucleotide, nucleotide affinity media and methods of use thereof for affinity chromatography and screening methods.Type: ApplicationFiled: January 21, 2004Publication date: October 28, 2004Applicant: Serenex, Inc.Inventors: Klass P. Hardeman, Steven E. Hall, Roy W. Ware, Lindsay A. Hinkley, Matthew G. Jenks
-
Patent number: 6716395Abstract: A method and apparatus are described for screening a proteome. The method and apparatus include an array of affinity elements, such that a proteome is directed through the array and those components that specifically bind to the affinity elements of the array are eluted in a suitable eluent by means of centrifugation. Suitable eluents can include a proteome component, a chemical library component or an affinity element. This method and apparatus can be used for several purposes, including screening for bio-active compounds, determining physiological targets of known drugs, determining specificity of compound interactions with physiological targets, and for quantitative protein analyses.Type: GrantFiled: December 18, 2001Date of Patent: April 6, 2004Assignee: Serenex, Inc.Inventors: Timothy A. J. Haystead, George J. Young
-
Publication number: 20030113938Abstract: A method and apparatus are described for screening a proteome comprising an array of affinity elements, whereby a proteome is directed through the affinity array and those components that specifically bind to the affinity array are eluted in a suitable eluent by means of centrifugation. Suitable eluents can include a proteome component, a chemical library component or an affinity element. This method and apparatus can be used for several purposes, including screening for bio-active compounds, determining physiological targets of known drugs, determining specificity of compound interactions with physiological targets, and for quantitative protein analyses.Type: ApplicationFiled: December 18, 2001Publication date: June 19, 2003Applicant: Serenex, Inc.Inventors: Timothy A. J. Haystead, George J. Young
-
Patent number: D545449Type: GrantFiled: February 15, 2005Date of Patent: June 26, 2007Assignee: Serenex, Inc.Inventors: William Edward Cosselmon, Stephen E. Allen, Timothy Shea Wadkins
-
Patent number: D563562Type: GrantFiled: February 15, 2005Date of Patent: March 4, 2008Assignee: Serenex, Inc.Inventors: William Edward Cosselmon, Stephen E. Allen, Robert Patrick Fadden, Jeffrey M. Partridge